909717-95-9

Basic information

• Product Name: 4-Methoxy-pyrazolo[1,5-a]pyridine-3-carboxylic acid ethyl ester
• Synonyms: 4-Methoxy-pyrazolo[1,5-a]pyridine-3-carboxylic acid ethyl ester;ethyl 4-methoxypyrazolo[1,5-a]pyridine-3-carboxylate
• CAS NO: 909717-95-9
• Molecular Formula: C11H12N2O3
• Molecular Weight: 220.22458
• Mol File: 909717-95-9.mol
• Article Data: 6

Chemical Properties

• Appearance: /
• Density: 1.24±0.1 g/cm3(Predicted)
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 0.27±0.30(Predicted)
• CAS DataBase Reference: 4-Methoxy-pyrazolo[1,5-a]pyridine-3-carboxylic acid ethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Methoxy-pyrazolo[1,5-a]pyridine-3-carboxylic acid ethyl ester(909717-95-9)
• EPA Substance Registry System: 4-Methoxy-pyrazolo[1,5-a]pyridine-3-carboxylic acid ethyl ester(909717-95-9)

Safety Data

• Hazardous Substances Data: 909717-95-9(Hazardous Substances Data)

Usage

General Description

4-Methoxy-pyrazolo[1,5-a]pyridine-3-carboxylic acid ethyl ester is a chemical compound with the molecular formula C11H11N3O3. It is an ester derivative of 4-methoxy-pyrazolo[1,5-a]pyridine-3-carboxylic acid and is commonly used as a building block in organic synthesis. 4-Methoxy-pyrazolo[1,5-a]pyridine-3-carboxylic acid ethyl ester has potential applications in the pharmaceutical industry, particularly in the development of new drugs and biologically active compounds. Its unique structure and properties make it a valuable tool for medicinal chemists and researchers in drug discovery. However, it is important to handle this chemical with care, as it may pose certain risks to human health and the environment.

Upstream product

• 81211-83-8 1-amino-5-methoxypyridinium 2,4,6-trimethylbenzenesulfonate 
• 623-47-2 propynoic acid ethyl ester 
• 7295-76-3 3-methoxypyridine 
• 91012-88-3 ethyl 2-(3-methoxypyridin-2-yl)acetate 

Downstream Products

• 141032-72-6 4-hydroxypyrazolo[1,5-a]pyridine 
• 51143-67-0 1-(pyrazolo[1,5-a]pyridin-4-yl)ethanone 

Relevant articles and documents

IMIDAZO[1,2-A]PYRIDINYL DERIVATIVES AS IRAK4 INHIBITORS

This invention relates to Imidazo[1,2-a]pyridinyl Derivatives of formula (I′), or pharmaceutically acceptable salts thereof, in which all of the variables are as defined in the specification, capable of modulating the activity of IRAK4. The invention further provides a method of manufacturing compounds of the invention, and methods for their therapeutic use. The invention further provides methods to their preparation, to their medical use, in particular to their use in the treatment and management of diseases or disorders including inflammatory disease, autoimmune disease, cancer, cardiovascular disease, a disease of the central nervous system, disease of the skin, an ophthalmic disease and condition, and a bone disease.

TDO2 INHIBITORS

Presently provided are inhibitors of cellularly expressed TDO2 and pharmaceutical compositions thereof, useful for modulating an activity of tryptophan 2, 3 dioxygenase; treating immunosuppression; treating a medical conditions that benefit from the inhibition of tryptophan degradation; enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent; and treating tumor-specific immunosuppression associated with cancer.

Phosphodiesterase inhibitors. Part 4: Design, synthesis and structure-activity relationships of dual PDE3/4-inhibitory fused bicyclic heteroaromatic-4,4-dimethylpyrazolones

(-)-6-(7-Methoxy-2-trifluoromethylpyrazolo[1,5-a]pyridin-4-yl)-5-methyl-4, 5-dihydro-3-(2H)-pyridazinone (KCA-1490) is a dual PDE3/4 inhibitor that exhibits potent combined bronchodilatory and anti-inflammatory activity. Here we show that a 4,4-dimethylpyrazolone subunit serves as an effective surrogate for the 5-methyl-4,5-dihydropyridazin-3(2H)-one ring of KCA-1490 whilst lacking a stereogenic centre. The 2- and 7-substituents in the pyrazolo[1,5-a]pyridine subunit markedly influence the PDE-inhibitory profile and can be adjusted to afford either potent PDE4-selective inhibitors or dual PDE3/4 inhibitors. A survey of bicyclic heteroaromatic replacements for the pyrazolo[1,5-a]pyridine allowed further refinement of the inhibitory profile and identified 3-(8-methoxy-2-(trifluoromethyl)imidazo[1,2-a]pyridin-5-yl)-4, 4-dimethyl-1H-pyrazol-5(4H)-one as an orally active, achiral KCA-1490 analog with well-balanced dual PDE3/4-inhibitory activity.